Get the Stockscreener App
1.25
0.79%
-0.01
After Hours:
1.26
0.01
+0.80%
Bioxcel Therapeutics Inc stock is traded at $1.25, with a volume of 605.02K.
It is down -0.79% in the last 24 hours and up +5.93% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$1.26
Open:
$1.26
24h Volume:
605.02K
Relative Volume:
0.41
Market Cap:
$33.84M
Revenue:
$642.00K
Net Income/Loss:
$-69.90M
P/E Ratio:
-0.1748
EPS:
-7.152
Net Cash Flow:
$-57.62M
1W Performance:
+17.92%
1M Performance:
+5.93%
6M Performance:
-32.80%
1Y Performance:
-26.90%
1-Day Range:
$1.25
$1.31
1-Week Range:
$1.02
$1.31
52-Week Range:
$1.01
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.25 | 34.11M | 642.00K | -69.90M | -57.62M | -7.152 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Rodman & Renshaw | Buy |
| Feb-21-24 | Downgrade | UBS | Buy → Neutral |
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
BioXcel Therapeutics, Inc. (BTAI) expected to beat earnings estimates: Should you buy? - MSN
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
BioXcel Shareholder Action Reminder - TMX Newsfile
BioXcel Shareholder Notice - TMX Newsfile
BTAI Forecast, Price Target & Analyst Ratings | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
BTAI: IGALMI targets a vast at-home market for acute agitation, with launch readiness for 2027 - TradingView
Transcript : BioXcel Therapeutics, Inc.Special Call - marketscreener.com
BTAI (BioXcel Therapeutics Inc.) reports narrower Q4 2025 loss than expected, shares gain 7.48 percent on upbeat investor reaction.NCAV - Xã Thanh Hà
BTAI BioXcel Therapeutics Inc. gains 7.48 percent after posting narrower than expected Q4 2025 EPS results. - Cổng thông tin điện tử tỉnh Tây Ninh
BioXcel Therapeutics, Inc. Enters Fourth Amended and Restated Registration Rights Agreement With Oaktree Investors - Minichart
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting - Sahm
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI in the At-Home Setting - 富途牛牛
BioXcel Therapeutics issues warrants to lenders as part of credit agreement amendment - Investing.com
Bioxcel Issues Warrants in Private Equity Financing Deal - TipRanks
BioXcel Therapeutics (NASDAQ: BTAI) grants 1,353,729 low-price warrants - Stock Titan
BioXcel to detail IGALMI launch strategy ahead of FDA decision By Investing.com - Investing.com Australia
H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns - Insider Monkey
BioXcel to detail IGALMI launch strategy ahead of FDA decision - Investing.com
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Bioxcel Therapeutics (BTAI) - The Globe and Mail
H.C. Wainwright reiterates BioXcel Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary D - GuruFocus
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - Sahm
BioXcel Therapeutics, Inc. (BTAI) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioXcel Therapeutics, Inc. (BTAI) stock price, news, quote and history - Yahoo Finance Australia
Jobs Data: Is BioXcel Therapeutics Inc a strong candidate for buy and hold2026 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn
BioXcel Therapeutics announces enrollment of first patients in U.S. Department of War-funded study of BXCL501 (sublingual dexmedetomidine) for treatment of acute stress reactions - marketscreener.com
BioXcel begins DoW-funded trial of BXCL501 for acute stress By Investing.com - Investing.com Canada
BioXcel drug enters U.S. military-funded study for acute stress after trauma - Stock Titan
BTAI Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel Therapeutics Inc. (BX20.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
BTAI Should I Buy - Intellectia AI
BTAI: HC Wainwright & Co. Lowers Price Target, Maintains Buy Rat - GuruFocus
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution - Investing.com
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
FDA accepts BioXcel filing for at-home agitation treatment By Investing.com - Investing.com South Africa
FDA accepts BioXcel filing for at-home use of agitation drug By Investing.com - Investing.com South Africa
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - Sahm
FDA accepts BioXcel filing for at-home use of agitation drug - Investing.com Australia
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):